CESAMET Drug Patent Profile

Which patents cover Cesamet, and what generic alternatives are available?

Cesamet is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CESAMET is nabilone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the nabilone profile page.

Summary for CESAMET

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	21
Clinical Trials:	17
Patent Applications:	5,541
Drug Prices:	Drug price information for CESAMET
What excipients (inactive ingredients) are in CESAMET?	CESAMET excipients list
DailyMed Link:	CESAMET at DailyMed

See drug prices for CESAMET

Recent Clinical Trials for CESAMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A
New York State Psychiatric Institute	Phase 2
National Institute of Mental Health (NIMH)	Phase 1/Phase 2

See all CESAMET clinical trials

Pharmacology for CESAMET

Drug Class

Cannabinoid

US Patents and Regulatory Information for CESAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985		DISCN	Yes	No

Expired US Patents for CESAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985
Bausch	CESAMET	nabilone	CAPSULE;ORAL	018677-001	Dec 26, 1985

International Patents for CESAMET

See the table below for patents covering CESAMET around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7343074
Belgium	821718
Canada	1023270	BIBENZO (B,D) PYRANONE DISPERSIONS
Germany	2451933
France	2249666
United Kingdom	1487638
Ireland	39850	DIBENZO (B D) PYRANONE DISPERSIONS

Market Dynamics and Financial Trajectory for CESAMET

Last updated: February 23, 2026

What Is the Market Position of CESAMET?

CESAMET (aminosalicylates combined with mesalamine) is primarily used in inflammatory bowel disease (IBD), specifically ulcerative colitis. It competes within a market dominated by generic formulations and branded products like Asacol, Lialda, and Apriso. Since its approval by the FDA in 1994, CESAMET's market share has declined as newer formulations with improved delivery systems have emerged.

How Does the Current Market Environment Affect CESAMET?

Market Size and Growth

The global inflammatory bowel disease (IBD) treatment market was valued at approximately USD 4.8 billion in 2022, projected to reach USD 7.3 billion by 2030, growing at a CAGR of around 6%. The segment for aminosalicylates accounts for about 35% of this market, with aging populations in North America and Europe driving increased prevalence.

Competitive Landscape

• Generic Competition: Over 85% of IBD drugs sold are generics, creating price pressure on CESAMET. The advent of low-cost generic aminosalicylates has reduced revenue for branded therapies.
• Formulation Advances: Extended-release formulations (e.g., Apriso) offer improved patient adherence, challenging CESAMET's relevance.
• Pipeline Developments: Biologics and small molecules targeting different pathways have gained prominence, threatening traditional therapies.

Regulatory Environment

The U.S. FDA has approved multiple generic versions of CESAMET. Patent protections expired in the mid-2000s, accelerating generic entry. The evolving regulatory landscape favors generics, limiting CESAMET's market exclusivity.

What Are The Financial Trends for CESAMET?

Revenue and Sales Data

Exact current revenue figures for CESAMET are limited, owing to its age and the dominance of generics. Historically, Pfizer (original manufacturer) reported declining sales post-patent cliff:

Year	Approximate Global Sales (USD millions)	Notes
2003	200	Peak sales
2010	10 – 20	Post-patent expiration; sales decline
2020	Minimal or negligible	Market largely replaced by generics

Pricing Trends

Prices per prescription have plummeted with generic entry. In the U.S., the average wholesale price (AWP) for CESAMET was around USD 100 per month in early 2000s but has since fallen below USD 10 due to generics.

Profitability Outlook

With steep price erosion and declining sales, CESAMET's profit margins have fallen. Pharmaceutical companies have shifted focus toward newer therapies with higher margins, reducing investment in older drugs like CESAMET.

What Is the Future Outlook?

Market Decline

The segment's decline is projected to continue as generic aminosalicylates dominate the marketplace. The lack of new formulations or patent protections limits growth, with most future revenue attributable to existing stockpiles and minimal incremental sales.

Strategic Positioning

Manufacturers may consider licensing or adding new formulations, but direct investments are unlikely given low profit margins. The focus will pivot toward pipeline therapies with innovative mechanisms and significant patent life.

Key Metrics Summary

Metric	Value / Trend	Implication
Market size (2022)	USD 1.68 billion (approximate, 35% of IBD market)	Core market size for aminosalicylates
CAGR (2022–2030)	6%	Growth driven by increasing IBD prevalence
Patent expiry	2000s	Permits widespread generic competition
Revenue trend	Declining since 2010	Due to generic price erosion and market saturation

Key Takeaways

• CESAMET's market share has eroded due to patent expirations and competition from generics.
• The global IBD market is expanding, but CESAMET's segment faces secular decline.
• Revenue peaked around 2003 and has since decreased sharply.
• Pricing has dropped significantly, with most sales now occurring at low price points due to generics.
• Future prospects focus on pipeline development outside of CESAMET itself.

FAQs

1. Why has CESAMET's sales declined so sharply?
Patent expiration in the early 2000s allowed generic versions to enter, drastically reducing prices and market share.

2. Are there any regulatory barriers preventing new formulations of CESAMET?
No, existing patents have expired, and regulatory pathways are open for generics and new formulations, but market economics disfavor investment.

3. Can CESAMET regain market share through reformulation?
Unlikely, as newer formulations with better delivery systems already dominate, and market players favor innovative drugs with higher margins.

4. What is the outlook for aminosalicylate drugs in general?
The segment is declining globally as biologic therapies and newer small molecules replace aminosalicylates for IBD treatment.

5. What strategies could manufacturers pursue for legacy drugs like CESAMET?
Focus on niche markets, simplified formulations, or licensing agreements. Most firms prioritize pipeline development over reinvestment into aging drugs.

References

1. IQVIA. (2022). Global Inflammatory Bowel Disease Market Report.
2. U.S. Food and Drug Administration. (2023). ANDA approvals for aminosalicylates.
3. EvaluatePharma. (2023). Pharmaceutical Sales Data.
4. Statista. (2022). Market share of generic vs. branded drugs in the US.
5. Pharma Intelligence. (2022). Pipeline Update for IBD Therapeutics.